7
Participants
Start Date
June 11, 2021
Primary Completion Date
March 5, 2024
Study Completion Date
March 5, 2024
GAd-PEV
Priming phase including 1 GAd-PEV administration with Standard of Care pembrolizumab (cycle 4).
MVA-PEV
Boosting phase including 3 boosting administrations of MVA-PEV with Standard of Care pembrolizumab (cycles 5, 6 and 7).
UZ Leuven Hospital, Campus Gasthuisberg, Herestraat 49, 3000 Leuven, Leuven
Grand Hopital de Charleroi, Grand Rue 3, 6000 Charleroi, Charleroi
START Madrid - Centro Integral Oncológico Clara Campal, HM CIOCC Hospital Universitario HM Sanchinarro, 28050 Madrid. Spain, Madrid
Instituto de Investigación Sanitaria INCLIVA - Hospital Clínico Universitario de Valencia. Av. Blasco Ibáñez, 17 CP 46010 Valencia, Spain, Valencia
Institut Catalá d'Oncologia ICO L'Hospitalet. Av Gran Via de L'Hospitalet 199-203. 08908 L'Hospitalet de Llobregat, Barcelona, Spain, Barcelona
START Madrid-FJD, Hospital Fundación Jiménez Diaz Avda. Reyes Católicos 2. 28040, Madrid, Spain, Madrid
Cancer Research UK Edinburgh Centre. Western General Hospital, Edinburgh, EH4 2SP, UK, Edinburgh
Lead Sponsor
Nouscom SRL
INDUSTRY